A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies

Exclusion Criteria

• •Subject must have received at least 2 prior regimens for their lymphoid malignancy, one of which was an anthracycline-containing combination regimen and have shown disease relapse or did not respond to the prior regimen
• •Subjects with classic HL or diffuse large B cell lymphoma must have failed, refused or are ineligible to receive stem cell transplant
• •Subjects must have measurable lesions (at least one target lesion measuring 2cm in diameter) by computerized tomography (CT) scan
• •Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• •All men of reproductive potential and women of child-bearing potential must agree to practice effective contraception during the entire study period and for one month after the last study treatment unless documentation of infertility exists. Additionally, women of child-bearing potential must have a negative pregnancy test within 14 days prior to the first dose of study drug
• •Able to understand and willing to sign the informed consent form
• •Post-Transplant Lymphoproliferative Disease (PTLD), Burkitt's lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma/leukemia, multiple myeloma, or HIV-associated lymphoma
• •History of or active Central Nervous System (CNS) malignancy
• •Have undergone allogeneic stem cell transplant and were treated with immunosuppressing agent within the past 6 months
• •Active Graft-versus-host disease (GVHD)
• +5 more criteria